Skip to search formSkip to main contentSkip to account menu

LY-2157299

Known as: LY 2157299, LY2157299 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PyrazolesQuinolines

Narrower (1)

galunisertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A pilot study of galunisertib (LY2157299 monohydrate) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC).
270 Background: TGF-β, the strongest known immunosuppressive cytokine, modulates the hepatic immune response to various antigens… 
2017
2017
Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in…
TPS501Background: Transforming growth factor-β (TGF-β) can suppress adaptive and innate anti-tumor immune responses. G (LY2157299… 
2016
2016
Galunisertib , a TGF-β receptor ( TβR )-I inhibitor , suppresses growth and invasion of an anaplastic thyroid cancer 8505 C cell in vitro and in vivo
Background and objective: The transforming growth factor-beta (TGF-β) signaling pathway is known to play a critical role in… 
2015
2015
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.
Transforming growth factor-β (TGF-β) signaling is associated with tumor progression and vascularization in malignant glioma. In… 
2013
2013
Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with…
2039 Background: Based on preclinical data suggesting an additive antitumor effect of combining TGF-s inhibitors with… 
2013
2013
Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in…
2061 Background: Based on preclinical data suggesting an additive antitumor effect of a TGF-s inhibitor and lomustine, a phase II… 
2013
2013
Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in…
2563 Background: Based on animal studies, the combination of a TGF-β inhibitor and gemcitabine is expected to enhance antitumor… 
2013
2013
Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma…
4118 Background: TGF-s signaling is associated with HCC progression in moderate to poorly differentiated tumors overexpressing… 
2013
2013
Abstract 2135: TGFβRI inhibition results in reduced collagen expression in pancreatic ductal adenocarcinoma.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Pancreatic ductal adenocarcinoma (PDAC) is… 
2005
2005
Targeting the TGF-β RI kinase with LY2157299: A PK/PD-driven drug discovery and clinical development program
SY13-2 Transforming growth factor-β (TGF-β) is a cytokine with diverse biological activities. TGF-β’s role as a tumor suppressor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)